drugset / Trial / NCT06894212
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Phase 3
Active not recruiting
538 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
RandomizedParallel-groupSingle-blindTreatment
Summary
Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia
Timeline
- Start
- 2025-02-28
- Primary completion
- 2026-10-20
- Completion
- 2026-10-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulotaront | Small molecule | 75 mg | — |
| Subject | Ulotaront | Small molecule | 100 mg | — |